Hyperbaric oxygen rescues lung cancer cells from chemical hypoxia-induced low differentiation and apoptosis resistance.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study with no human subjects
PubMed 30739528 · doi:10.1080/01902148.2019.1571124
What was done
The authors investigated the effects of hyperbaric oxygen (HBO) on A549 lung cancer cells exposed to chemical hypoxia induced by cobalt chloride (CoCl2). They assessed hypoxia-inducible factor-1α (HIF-1α) expression, lactate dehydrogenase (LDH) activity, cell migration and invasion capacity, epithelial-mesenchymal transition (EMT) markers (E-cadherin/N-cadherin ratio), and apoptotic markers (Bcl-2/Bax ratio and GRP78 expression) in CoCl2-treated cells with or without HBO treatment.
What was found
No quantitative values, effect sizes, or p-values are reported in the abstract. CoCl2-induced chemical hypoxia resulted in increased LDH activity, migration, invasion, Bcl-2/Bax ratio, and GRP78 expression, along with a decreased E-cadherin/N-cadherin ratio. HBO treatment attenuated the increases in LDH activity, migration, and invasion, restored the E-cadherin/N-cadherin ratio and EMT phenotype, normalized the Bcl-2/Bax ratio, and repressed GRP78 expression.
Why it matters
This study outlines a mechanistic basis by which hyperbaric oxygen can reverse hypoxia-induced invasiveness, EMT, and apoptotic resistance in lung cancer cells in vitro, supporting further investigation into oxygenation strategies as adjuvant cancer therapies.
Limits
This is an in vitro cell culture study limited to a single cell line (A549) and a chemical model of hypoxia (CoCl2), which does not replicate the complex in vivo tumor microenvironment. The abstract does not report numerical data, sample sizes, or replication counts.
Cited by
- supports Hyperbaric oxygen therapy decreases lactate concentrations in the tumor microenvironment.